Daewoong To Sell Medivir 's Xerclear in Korea As Swedish Firm Looks For More Partners
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Daewoong Pharmaceutical - one of the leading local pharmas - signed an agreement with Medivir to sell the latter's OTC cold sore treatment Xerclear (acyclovir and hydrocortisone) in Korea, as Medivir continues to seek partners for the drug outside of its primary markets
You may also be interested in...
Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter
SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices
Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter
SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices
GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products
GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category